Clinical Study

Echocardiographic Findings and Their Impact on Outcomes of Critically Ill Patients with AIDS in the Era of HAART

Abubakr A. Bajwa, James D. Cury, Lisa Jones, Adil Shujaat, and Faisal Usman

Shands Hospital, College of Medicine, University of Florida, 655 West 8th Street, Jacksonville, FL 32209, USA

Correspondence should be addressed to Abubakr A. Bajwa, abubakr.bajwa@jax.ufl.edu and Faisal Usman, faisal.usman@jax.ufl.edu

Received 23 December 2011; Revised 6 February 2012; Accepted 7 February 2012

Academic Editor: Dimitris Georgopoulos

Copyright © 2012 Abubakr A. Bajwa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To describe the echocardiographic findings in critically ill patients with AIDS and their impact on clinical outcome.

Design. A retrospective chart review of consecutive AIDS patients over 18 years of age, who had a trans-thoracic echocardiogram performed during the course of intensive care unit stay over the course of 2 years at a tertiary care hospital.

Main outcome measures. The prevalence of echocardiogram abnormalities in this population and its impact on ICU mortality, ICU length of stay, hospital mortality, hospital length of stay and 60 day survival.

Results. Among 107 patients who met the inclusion criteria, an admission echocardiogram was performed in 62 (58%). The prevalence of cardiac abnormalities was 60%. The most common admission diagnosis was respiratory failure \( n = 27 \) (43%). The most common finding on echocardiogram was left ventricular (LV) dysfunction \( n = 31 \) (50%) followed by pulmonary hypertension \( n = 25 \) (40%). None of these findings had a significant impact on clinical outcomes. There was trend toward reduced 60 day survival among patients with depressed LV function.

Conclusions. Although echocardiogram abnormalities were prevalent among this population none of these findings had a significant impact on ICU mortality or hospital mortality and ICU length of stay or hospital length of stay.

1. Introduction

The CDC estimates that 56,300 new HIV infections occurred in the United States in 2006 [1]. In the era of highly active antiretroviral therapy the mortality from HIV has been decreasing [2–6]. More patients are admitted to the intensive care unit for non-AIDS-associated illnesses than in the past [2, 5–8]. Advances in echocardiogram technology have provided the critical care physicians with a reliable and noninvasive method of determining cardiac function and chamber sizes and to detect the presence of valve diseases and pericardial disease. Due to its ready availability and noninvasive nature, echocardiography is commonly used in the critically ill population. A number of echocardiogram findings have been described in the noncritically ill HIV population with the most common ones being pericardial effusion, myocarditis, dilated cardiomyopathy, endocarditis, and pulmonary hypertension, while a recent prospective observational study showed that 18% of the HIV patients had systolic, 26% had diastolic dysfunction, and up to 57% had evidence of pulmonary hypertension based on TR jet velocity [9, 10]. Pericardial effusion has also been shown to predict increased mortality among HIV infected patients [11, 12]. Blanc et al. performed a prospective echocardiographic study in HIV patients admitted to the intensive care unit (ICU) preceding the highly active antiretroviral therapy (HAART) era and found a similar prevalence of cardiac abnormalities as previously published studies [13]. Hakim et al. presented an abstract of echocardiographic findings in hospitalized HIV patients which showed that 50% of the patients have echocardiographic abnormalities [14]. The prevalence of pulmonary hypertension in HIV-infected patients which showed that 50% of the patients have echocardiographic abnormalities [14]. The prevalence of pulmonary hypertension in HIV-infected patients has changed little from the 1990s (0.5%), when HAART therapy was not readily available to the 2000s (0.46%), when HAART therapy is easily available [15, 16]. The prevalence of pulmonary hypertension in critically ill patients with AIDS is not known.

Acquired immunodeficiency syndrome (AIDS) represents the most advanced part of the spectrum of HIV infected
population. The CDC estimates that in 2006 there were 436,693 persons living with AIDS in the United States. More AIDS patients get admitted to the intensive care unit due to the changing spectrum of management in this era due to availability of HAART therapy. Afessa et al. showed that in their center higher APACHE II scores and transfer from another hospital were associated with poor outcome [4] however like most other studies, this study included patients with HIV infection with or without AIDS. To date no studies have described echocardiographic findings in critically ill patients with AIDS in the HAART era and their impact on clinical outcomes.

2. Methods

After approval by the institutional review board, we performed a retrospective analysis of consecutive AIDS patients admitted to the medical intensive care unit of an urban tertiary care center from 2005–2008. Patients who did not have an echocardiogram done during ICU admission were excluded from the analysis. We collected demographics data, admission diagnoses and calculated the Acute Physiology and Chronic Health Evaluation (APACHE 2) Score. We also documented ICU mortality, hospital mortality, and 60-day survival. The use of HAART therapy, compliance with HAART therapy, CD4 count, and HIV viral loads were also recorded. The echocardiographic findings were documented after a review of the echocardiogram reports. We also documented the presence and severity of pericardial effusion, right atrial dilation, left atrial dilation and size in cm, evidence of pulmonary hypertension as defined by TR jet velocity greater than 2.5 meters per second (m/sec), estimated pulmonary artery systolic (PAS) pressure, TR jet velocity in m/s, right ventricular (RV) dilation, RV dysfunction, left ventricular (LV) dilation, LV end systolic (ES) and end diastolic (ED) size in cm, LV ejection fraction (EF), and LV fractional shortening in percentage. LV ejection fraction measurements from echocardiogram results were categorized as normal (≥55%), mildly depressed (45%–54%), moderately depressed (35%–44%), and severely depressed (<35%). We performed a descriptive and comparative analysis of the data. Mean and range or standard deviation was used to describe normally distributed continuous data. Median and interquartile range (IQR 25–75) was used to describe nonnormally distributed data, and percentages were used to describe categorical data. A logistic regression analysis was performed to evaluate the impact of multiple echocardiogram parameters on ventilator days, ICU mortality, hospital mortality, and length of stays both in the ICU and hospital. A P value less than .05 was considered statistically significant. A logistic regression analysis was performed to analyze the relationship between variables. Statistical analysis was performed using JMP (Statistical Discovery by SAS, Cary, NC, USA).

3. Results

From 2005 to 2008, there were 107 AIDS patients admitted to the medical ICU at our institute. 62 (58%) of these patients had at least one echocardiogram done upon their admission to the ICU and were included in the analysis. Demographics are described in Table 1. The majority of the patients were male (70%) and black (90%). Only a small number of these patients was on HAART therapy n = 19 (31%), and only 10 of 19 (53%) were compliant with therapy based on documentation upon admission to the ICU. The most common diagnosis was respiratory failure n = 27 (43%) (Table 2). Mechanical ventilation was instituted in 43 of 62 (68%) patients with median ventilator days of 3 (IQR 2–7). The report of the first echocardiogram done during the ICU stay was reviewed, and the predefined data were collected. The echocardiogram was considered abnormal in 38 patients (60%), with the most common abnormality being left ventricular dysfunction n = 31 (50%) followed by evidence of pulmonary hypertension n = 25 (40%) and pericardial

| Table 1: Demographics, length of stay, and mortality. |
|-----------------------------------------------------|
| Age, yrs. mean ± SD | 47 ± 9 |
| Sex | |
| Male, number (%) | 44 (70) |
| Female, number (%) | 18 (29) |
| Race | |
| Black, number (%) | 56 (90) |
| Caucasian, number (%) | 6 (10) |
| HAART therapy | |
| Yes | 19 (31) |
| No | 43 (70) |
| CD4 count, mean ± SD | 95 ± 141 |
| HIV viral load, copies/mL. mean ± SD | 326270 ± 561689 |
| APACHE II score, mean ± SD | 23.4 ± 9.3 |
| APACHE II predicted mortality, mean ± SD | 47 ± 26 |
| ICU LOS, median (IQR 25–75) | 3 (2–7) |
| Hospital LOS, median (IQR 25–75) | 10 (5–19) |
| Ventilator days, median (IQR 25–75) | 3 (2–7) |
| ICU mortality, number (%) | 21 (33) |
| Hospital mortality, number (%) | 21 (33) |
| LOS: length of stay; HAART: highly active antiretroviral therapy. |

| Table 2: Admission diagnosis. |
|-----------------------------|
| Diagnosis | Number (% ) |
| Respiratory failure | 27 (43) |
| Altered mental status | 9 (14) |
| Sepsis | 9 (14) |
| Pneumonia | 4 (7) |
| Seizure | 4 (7) |
| GI bleed | 2 (3) |
| Ascites | 2 (3) |
| Spinal cord compression | 1 (1.6) |
| Diarrhea | 1 (1.6) |
| Pneumothorax | 1 (1.6) |
| Syncope | 1 (1.6) |
| Paraplegia | 1 (1.6) |
Pulmonary Medicine

Table 3: Echocardiogram findings.

| Findings                                      | Number (%) |
|-----------------------------------------------|------------|
| Pericardial effusion, number (%)              | 14 (22)    |
| Moderate size                                 | 1 (7)      |
| Small size                                    | 13 (93)    |
| Pulmonary HTN, number (%)                     | 25 (40)    |
| Estimated PA systolic pressure mm Hg, mean ± SD| 45 ± 12    |
| TR jet velocity m/sec, mean ± SD              | 2.9 ± 0.3  |
| RA dilatation, number (%)                     | 16 (26)    |
| Mild                                          | 14 (87)    |
| Marked                                        | 2 (13)     |
| Right ventricular enlargement, number (%)     | 11 (18)    |
| Mild                                          | 9 (82)     |
| Moderate                                      | 2 (18)     |
| Right ventricular dysfunction, number (%)     | 2 (4)      |
| Mild                                          | 1 (50)     |
| Severe                                        | 1 (50)     |
| LA size in cm, mean ± SD                      | 3.7 ± 0.7  |
| LA dilation, number (%)                       | 19 (31)    |
| Mild                                          | 11 (58)    |
| Moderate                                      | 6 (32)     |
| Severe                                        | 2 (10)     |
| LV size in cm, mean ± SD                      | 3.4 ± 1.1  |
| End systolic                                  | 4.8 ± 0.8  |
| LV ejection fraction (LVEF) %, mean ± SD      | 51 ± 19    |
| LV fractional shortening %, mean ± SD         | 33 ± 11    |
| LV dysfunction, number (%)                    | 31 (50)    |
| Mildly depressed LVEF                         | 6 (19)     |
| Moderately depressed LVEF                    | 8 (26)     |
| Severely depressed LVEF                      | 8 (26)     |
| Hyperkinetic                                  | 8 (25)     |
| Diastolic dysfunction                         | 1 (3)      |

PA: pulmonary artery, TR: tricuspid regurgitation, LA: left atrium, and LV: left ventricle.

Some patients had more than one echocardiographic finding.

Figure 1: Kaplan-Meier survival curve for patients with echocardiographic findings of depressed LV function and normal LV function.

4. Discussion

This is the first study to look at the echocardiographic findings and its impact on clinical outcomes in critically ill patients with AIDS in the era of HAART. Advances in critical care medicine over the last two decades have resulted in improved outcomes of patients with HIV infection and AIDS. Echocardiography these days is done on almost every patient admitted to the intensive care units. The information obtained from the echocardiogram does guide treatment in majority of these patients and HIV patients are not different [13]. The first cardiac manifestation of AIDS was described in 1983 by Autran et al., when they published a case of cardiac Kaposi sarcoma in a Haitian woman [17]. Since then, a number of studies have estimated the prevalence of cardiac involvement in AIDS patients to range from 28% to 73% [9, 11–13]. Echocardiographic abnormalities among hospitalized HIV population are reported to be around 50% in two different studies [13, 14]. The prevalence of abnormal echocardiogram in our AIDS population was slightly higher than previously reported for HIV population admitted to the ICU by Blanc et al. [13]. In the study by Blanc et al., pericardial effusion was the most common (29%) abnormality followed by LV dysfunction (22%). In the same study vegetations were noted in 3%, and sepsis was the leading cause of admission to the ICU (90%). In our study LV dysfunction (50%) and pulmonary hypertension (40%) were the most common abnormalities. No vegetations were noted. The higher
prevalence of LV dysfunction in this group may reflect the availability of HAART, longer life span of AIDS patients, and acquiring the infection at a later age. However in our cohort, only 30% of our patient population was actually on drugs, and even a smaller number were actually compliant with therapy, making it possible that the lack of adequate control of HIV infection may be the cause of the critical illness and higher prevalence of echocardiographic abnormalities. Another factor to be considered is the presence of sepsis at the time of admission in our population. Myocardial dysfunction has been well documented in sepsis the spectrum of dysfunction ranges from hyperkinetic function to depressed EF [18]. It is difficult to ascertain whether these abnormalities were related to the underlying critical illness or to HIV infection itself. We were able to compare echocardiograms done during critical illness to a prior echocardiogram in 23 (36.5%) of the cases and almost all of them had similar abnormalities documented. Due to the design of the study, we were unable to evaluate whether or not these abnormal findings on echocardiogram resulted in any change in management strategy. Another noteworthy finding was the high prevalence of moderate pulmonary hypertension by echocardiogram (40%) in this population. The prevalence of pulmonary hypertension in noncritically ill HIV population ranges from 0.03% to 7% in different eras of HIV treatment and from various regions of the world [19–22]. Although right heart catheterization remains to be gold standard for diagnosis of pulmonary arterial hypertension, an echocardiogram has been routinely used in studies to screen for pulmonary hypertension in otherwise healthy HIV patients. In this critically ill population the presence of pneumonia, respiratory failure, mechanical ventilation along with high number of concomitant LV dysfunction rather than true pulmonary arterial hypertension, likely explain the high prevalence of pulmonary hypertension noticed on echocardiogram.

There are several limitations to this study. The retrospective nature limits the ability to derive any conclusion in regards to whether the findings noticed on echocardiogram lead to any management change during the course of ICU stay and hence limiting our ability to determine the impact of these findings on clinical outcome. There was also no way to determine whether standardized echocardiography techniques were uniformly employed to obtain images.

Based on our review, there was no prognostic significance of any single echocardiogram abnormality in this AIDS population. Whether an echocardiogram performed in the ICU in this critically ill AIDS population leads to findings that can significantly impact management decision remains to be seen.

Conflict of Interests

The authors declare that there is no conflict of interest.

References

[1] H. I. Hall, R. Song, P. Rhodes et al., “Estimation of HIV incidence in the United States,” Journal of the American Medical Association, vol. 300, no. 5, pp. 520–529, 2008.

[2] M. Narasimhan, A. J. Posner, V. A. DePalo, P. H. Mayo, and M. J. Rosen, “Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy,” Chest, vol. 125, no. 5, pp. 1800–1804, 2004.

[3] A. Morris, J. Creasman, J. Turner, J. M. Luce, R. M. Wachter, and L. Huang, “Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 3, pp. 262–267, 2002.

[4] B. Afessa and B. Green, “Clinical course prognostic factors and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study,” Chest, vol. 118, no. 1, pp. 138–145, 2000.

[5] E. Casalino, M. Wolff, P. Ravaud, C. Choquet, F. Bruceel, and B. Regnier, “Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit,” AIDS, vol. 18, no. 10, pp. 1429–1433, 2004.

[6] L. Huang, A. Quartin, D. Jones, and D. V. Havlir, “Intensive care of patients with HIV infection,” New England Journal of Medicine, vol. 355, no. 2, pp. 173–181, 2006.

[7] R. Nuesch, N. Geigy, E. Schaedler, and M. Battegay, “Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 21, no. 9, pp. 684–687, 2002.

[8] R. Palacios, A. Hidalgo, C. Reina, M. V. de la Torre, M. Márquez, and J. Santos, “Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit,” HIV Medicine, vol. 7, no. 3, pp. 193–196, 2006.

[9] P. Rerkpattanapipat, N. Wongpraparut, L. E. Jacobs, and M. N. Kotler, “Cardiac manifestations of acquired immunodeficiency syndrome,” Archives of Internal Medicine, vol. 160, no. 5, pp. 602–608, 2000.

[10] K. E. Mondy, J. Gottdiener, E. T. Overton et al., “High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 52, no. 3, pp. 378–386, 2011.

[11] P. A. Heidenreich, M. J. Eisenberg, L. L. Kee et al., “Pericardial effusion in AIDS: incidence and survival,” Circulation, vol. 92, no. 11, pp. 3229–3234, 1995.

[12] B. Longo-Mbenza, K. V. Seghers, M. Phuati, F. Nkibungu Bikangi, and K. Mubagwa, “Heart involvement and HIV infection in African patients: determinants of survival,” International Journal of Cardiology, vol. 64, no. 1, pp. 63–73, 1998.

[13] P. Blond, A. Boussuges, J. Souk-Aloun, B. A. Gaüzere, and J. M. Sainty, “Echocardiography on HIV patients admitted to the ICU,” Intensive Care Medicine, vol. 23, no. 12, pp. 1279–1281, 1997.

[14] J. G. Hakim, J. A. Matenga, and S. Siziya, “Myocardial dysfunction in HIV infection: an echocardiographic study of 157 hospitalized patients in Zimbabwe,” in Proceedings of the International AIDS Conference, vol. 11, p. 102, 1996.

[15] R. Speich, R. Jenni, M. Opravil, M. Pfab, and E. W. Russi, “Primary pulmonary hypertension in HIV infection,” Chest, vol. 100, no. 5, pp. 1268–1271, 1991.

[16] O. Sitbon, C. Lascoux-Combe, J. F. Delfrassy et al., “Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 108–113, 2008.

[17] B. Autran, I. Gorin, and M. Leibowitch, “AIDS in a Haitian woman with cardiac Kaposi’s sarcoma and Whipple’s disease,” Lancet, vol. 1, no. 8327, pp. 767–768, 1983.
[18] A. Rudiger and M. Singer, “Mechanisms of sepsis-induced cardiac dysfunction,” Critical Care Medicine, vol. 35, no. 6, pp. 1599–1608, 2007.

[19] M. Humbert, O. Sitbon, A. Chaouat et al., “Pulmonary arterial hypertension in France: results from a national registry,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 9, pp. 1023–1030, 2006.

[20] O. Sitbon, C. Lascoux-Combe, J. F. Delfraissy et al., “Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 108–113, 2008.

[21] M. Opravil and D. Sereni, “Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era,” AIDS, vol. 22, no. 3, supplement, pp. S35–S40, 2008.

[22] R. Speich, R. Jenni, M. Opravil, M. Pfäb, and E. W. Russi, “Primary pulmonary hypertension in HIV infection,” Chest, vol. 100, no. 5, pp. 1268–1271, 1991.